^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Transcriptomic signature predicts the distant relapse in patients with ER+ breast cancer treated with tamoxifen for five years

Excerpt:
...a multi‑gene expression based risk score was developed and was revealed as being able to successfully predict the outcome of patients with ER+ breast cancer treated with tamoxifen for 5 years.
DOI:
doi.org/10.3892/mmr.2017.8234